PR Newswire/Les Echos/
Combined General Shareholder Meeting of May 3, 2013
* Shareholder approval of the financial statements for 2012
* Dividend of EUR2.77 per share payable as of May 14, 2013
* Nomination of a new director, Ms. Fabienne Lecorvaisier
Paris, France - May 3, 2013 - Sanofi (EURONEXT : SAN et NYSE : SNY) announced
its Combined General Shareholder Meeting was held today at the Palais des
Congrès in Paris. All resolutions were adopted by its shareholders.
During the meeting, shareholders approved, among other resolutions, the
corporate and consolidated financial statements for the year 2012. At the
General Meeting, shareholders decided the distribution of a cash dividend in
the amount of EUR 2.77 per share which will be detached on Euronext Paris on
May 9, 2013 with payment as of May 14, 2013.
The General Meeting also approved the appointment of Ms. Fabienne Lecorvaisier
as a Director, for a term of four years, i.e., until the General Meeting called
to approve the financial statements for the year 2016.
After the Shareholder Meeting, the new Board of Directors is comprised of 16
members, of whom four are women and ten are independent Directors. It consists
of the following members :
* Serge Weinberg, Chairman of the Board of Directors
* Christopher Viehbacher, Chief Executive Officer
* Laurent Attal
* Uwe Bicker *
* Robert Castaigne *
* Thierry Desmarest
* Lord Douro *
* Jean-René Fourtou *
* Claudie Haigneré *
* Igor Landau
* Fabienne Lecorvaisier *
* Suet-Fern Lee *
* Christian Mulliez
* Carole Piwnica *
* Klaus Pohle *
* Gérard Van Kemmel *
During the Board of Directors session following the meeting, Ms. Fabienne
Lecorvaisier was appointed member of the Audit Committee.
The voting results will be available on the company's website (www.sanofi.com)
in the coming days.
The audiocast of the Combined General Shareholder Meeting is available on the
Company's website (www.sanofi.com).
(* Independent Director)
Sanofi, an integrated global healthcare leader, discovers, develops and
distributes therapeutic solutions focused on patients' needs. Sanofi has core
strengths in the field of healthcare with seven growth platforms: diabetes
solutions, human vaccines, innovative drugs, consumer healthcare, emerging
markets, animal health and the new Genzyme. Sanofi is listed in Paris
(EURONEXT: SAN) and in New York (NYSE: SNY).
Relations Presse Relations Investisseurs
Jean-Marc Podvin Sébastien Martel
+ (33) 1 53 77 46 46 + (33) 1 53 77 45 45
The content and accuracy of news releases published on this site and/or
distributed by PR Newswire or its partners are the sole responsibility of the
originating company or organisation. Whilst every effort is made to ensure the
accuracy of our services, such releases are not actively monitored or reviewed
by PR Newswire or its partners and under no circumstances shall PR Newswire or
its partners be liable for any loss or damage resulting from the use of such
information. All information should be checked prior to publication.
-0- May/06/2013 07:58 GMT
Press spacebar to pause and continue. Press esc to stop.